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Abstract 
 
Background: Evidence about inhibitor formation in non-severe haemophilia and the potential role for 
clotting factor concentrate type is scant. 
 
Aim: To report inhibitor development in non-severe haemophilia patients enrolled in the European 
Haemophilia Safety Surveillance (EUHASS) study. 
 
Methods: Inhibitors are reported quarterly and total treated patients annually. Incidence rates and 
95% Confidence Intervals (95% CI) were calculated according to diagnosis and concentrate used. 
 
Results: Between 1-10-2008 and 31-12-2012, 68 centres reported on 7969 patients with non-severe 
haemophilia A and 1863 patients with non-severe haemophilia B. For haemophilia A, 37 inhibitors 
occurred in 8622 treatment years, resulting in an inhibitor rate of 0.43/100 treatment years (95% CI 
0.30-0.59). Inhibitors occurred at a median age of 35 years, after a median of 38 exposure days (EDs; 
P25-P75: 20-80); with 72% occurring within the first 50 EDs. In haemophilia B, one inhibitor was 
detected in 2149 treatment years, resulting in an inhibitor rate of 0.05/100 years (CI 0.001-0.26). This 
inhibitor developed at age 6 years, after 6 EDs. The rate of inhibitors appeared similar across 
recombinant and plasma derived FVIII concentrates. Rates for individual concentrates could not be 
calculated at this stage due to low number of events.  
 
Conclusion: Inhibitors in non-severe haemophilia occur three times more frequently than in 
previously treated patients with severe haemophilia at a rate of 0.43/100 patient years (haemophilia 
A) and 0.05/100 years (haemophilia B). Although the majority of Inhibitors developed in the first 50 
EDs, inhibitor development continued with increasing exposure to FVIII.  
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Introduction: 
Haemophilia is a rare disease affecting 1 in 10,000 (haemophilia A) and 1 in 50,000 (haemophilia B) 
individuals, of which 50-60% have moderate or mild disease with Factor VIII or IX activity levels of 1-
40%(1-3) . Since the development of cryoprecipitate in the 1960s and clotting factor concentrates in 
the 1970s, effective replacement therapy is available. This together with the development of home-
treatment and prophylaxis has dramatically improved outcome and quality of life(4-5). Since the 
introduction of viral inactivation in the mid-1980s, the development of anti-factor VIII inhibitors has 
remained as the most frequent adverse effect of haemophilia treatment, especially in severe 
haemophilia A. During the first 50 exposure days (ED) to concentrate 25-32% of patients with severe 
haemophilia A and 5-10% of patients with severe haemophilia B develop inhibitors(6-8) . In patients 
with longer exposure to factor concentrates (previously treated patients) a lower incidence of 1-5 per 
1000 treatment years was observed(9).  
Based on much less data than in severe haemophilia, the cumulative incidence of inhibitor 
development in moderate and mild haemophilia is estimated to be 3-13% (10-12)  . Several national 
registries reported that 28-29% of all inhibitors reported occurred in non-severe haemophilia 
patients(13-14). In clinical practice, inhibitors often cause spontaneous and major bleeding 
complications, as endogenous FVIII activity is reduced in the majority of patients, often to the level of 
severe haemophilia(14). Data on results of eradication treatment are lacking(10). 
Non-severe haemophilia patients may have a lower inhibitor risk due to the combination of less 
frequent exposure to treatment and the presence of endogenous FVIII/FIX activity since before birth, 
which may induce tolerance. In addition to endogenous risk factors such as FVIII gene mutation, 
which has been shown to correlate to inhibitor risk both in severe(15) and in non-severe 
patients(12), treatment-related factors such as intensive treatment are also important determinants 
of inhibitor risk(16-17). In this context, many have proposed a role for FVIII concentrate type in 
inhibitor development. However, these reports have almost exclusively focused on severe patients. 
In this patient group, contradictory data have been published suggesting increased inhibitor 
development on recombinant FVIII concentrates compared to plasma derived FVIII concentrates(18-
19); and on Kogenate Bayer/Helixate NextGen in previously untreated patients (PUPs) (20-23) , as 
well as on the role of B-domain deleted products (BDD rec FVIII)/Refacto and inhibitor risk in 
previously treated patients (PTPs)(9,24-25) .  
Treatment related adverse events, including inhibitor development, are best addressed by 
prospective surveillance strategies or large cohort studies(8,26) The European Haemophilia Safety 
Surveillance (EUHASS) commenced in 2008 to monitor treatment safety in a large number of sentinel 
haemophilia centres in Europe(23,27).  
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The present study presents the first four-year results of monitoring for inhibitor development in non-
severe haemophilia in the EUHASS registry. 
 
 
Methods: 
The design of the EUHASS study has already been reported (27). EUHASS is an international 
multicentre pharmaco-surveillance system covering an open population. Briefly, data collection 
started on October 1st 2008, or subsequent years for centres that joined EUHASS later.  Participating 
centres provided reports on all new inhibitors diagnosed at the centre every three months, using a 
secure web-based data-entry system. Inhibitors were defined as two consecutive tests above the 
local laboratory threshold; information on recovery tests was not collected, nor was central 
laboratory confirmation performed. For each patient with an inhibitor, anonymised data on age, type 
and severity of haemophilia, cumulative number of EDs to FVIII/FIX concentrate before inhibitor 
development (for each concentrate used), the date of the last negative inhibitor titre, the dates and 
titres of the first two positive inhibitor titres, the type of inhibitor test used, and the local threshold 
for positive inhibitor testing were collected. EDs were recorded up to 1000 EDs, and coded as >999 
EDs for patients with 1000 EDs or more. Only new inhibitors with positive titres on two occasions 
were considered. 
Data on the number of patients at risk of inhibitor development are collected annually.  
For patients with mild and moderate haemophilia, the number of patients receiving treatment 
without inhibitor development is established by subtracting the number of severe haemophilia 
patients treated from the total number of patients treated in the year; this calculation is performed 
for the whole population and for each concentrate. As details on the number of exposures at patient 
level are unavailable, exposure to concentrates is expressed as treatment years. 
Logical checks, as well as checks for completeness of data are performed on each adverse event at 
the time of reporting. In 2013, all centres were asked to confirm accuracy and completeness of their 
data on adverse events and patients at risk entered up to 31st December 2012. Only data from 
centres with fully checked data and resolution of all queries are included in this analysis. Prior to 
study entry all centres had to approach their institutional review board for approval. Regulations in 
the 26 European Countries participating vary and for the majority of centres no formal approval was 
required. If required, approval was obtained before study participation. 
 
Statistical analysis: 
As some of the variables had a skewed distribution, descriptive statistics were presented as medians 
and interquartile ranges (presented as P25-P75). The inhibitor rate per 100 treatment-years was 
6 
 
calculated for each concentrate. The total observation period was 4.25 years, as the fourth year of 
the registry covered the period from 1st Oct 2011 to 31st December 2012. 95% Confidence Intervals 
(CI) were calculated using the exact method (28). All analyses were performed using SPSS version 20. 
 
Results 
The number of centres reporting full data on non-severe haemophilia patients increased since 2008 
from 49 to 74. Failure to confirm submitted data resulted in exclusion of all data from six centres, 
which reported an additional eight inhibitors without providing denominator data. The dataset used 
for this report represents 92% of centres, 90% of registered patients and 83% of all inhibitors 
reported in non-severe haemophilia patients. An overview of data analysed and inhibitors reported 
according to diagnosis is shown in Table 1. 
In total, these centres reported on 7969 patients with moderate or mild haemophilia A (8622 
treatment years, 39 inhibitors) and 1863 patients with moderate or mild haemophilia B (2149 
treatment years, 1 inhibitor).  
 
Characteristics of patients developing inhibitors and the number of inhibitors are shown in Table 2.  
In patients with non-severe haemophilia A, 14 (36%) of inhibitors were observed in patients with 
moderate haemophilia (FVIII activity 1-5%) and 25 (64%) in patients with mild haemophilia (FVIII 
activity 6-40%). Patients developed inhibitors at a median age of 35.3 years, after a median of 38 EDs 
(P25-P75: 20-80); 72% (28/39) of inhibitors occurred before reaching 50 EDs, but 15% occurred after 
the first 100 EDs. The median first inhibitor titre was 4 BU/mL, including 51% with a high titre 
inhibitor (above 5 BU/mL). One inhibitor was observed in a patient with mild haemophilia B; this 
inhibitor developed at age 26 years, only after 6 EDs. Inhibitor rates between moderate and mild 
haemophilia patients could not be compared as treatment data were reported according to 
concentrate only, and not according to haemophilia severity. 
 
Inhibitor development according to concentrate types and individual recombinant concentrates is 
shown in Table 3. The 39 inhibitors observed in patients with haemophilia A included 34 in patients 
treated with recombinant FVIII and five inhibitors in patients treated with plasma-derived 
concentrates. These included two inhibitors in patients with moderate haemophilia A treated with 
Haemate P. EUHASS collects data on number of haemophilia patients treated with Haemate P per 
year. However it was observed that the numbers of patients treated with Haemate P reported were 
inconsistent in many of the centres, possibly caused by inadverted inclusion of patients with von 
Willebrand disease in the annual reports. Therefore it was decided that the inhibitor rate for 
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Haemate P could not be reliably calculated from the current data, and data on Haemate P were 
excluded from the calculations of inhibitor rates in non-severe haemophilia A. 
The 37 inhibitors analysed occurred in 8622 treatment years, resulting in an inhibitor rate of 
0.43/100 treatment years (CI 0.30-0.59). As not all patients received clotting factor concentrates 
each year, the annual inhibitor rate for patients registered was lower at 0.11/100 patients/year.  
When comparing inhibitor development according to concentrate, the inhibitor rate appeared lower 
in patients treated with plasma-derived concentrates, but with overlapping 95% confidence intervals 
(0.52/100 years (CI 0.36-0.73) for recombinant concentrates and 0.14/100 years (CI 0.03-0.42) for 
plasma derived concentrates. After exclusion of data on Haemate P, inhibitors developed on only 
two (Aafact and Factane) of 15 plasma derived concentrates with a total number of treatment years 
ranging from 3 to 580 per concentrate and overlapping confidence intervals for inhibitor rates 
(Aafact 3.48/100 years (CI 0.09-17.92) and Factane (0.70/100 years (CI 0.08-2.51)). Details on 
inhibitor development on plasma derived FVIII and FIX concentrates are shown in the appendix. 
Plasma-derived concentrates were used in almost all centres. 
For patients with non-severe haemophilia B, only one inhibitor was detected in 2149 treatment 
years, resulting in an inhibitor rate of 0.05/100 treatment years (CI 0.001-0.26). The annual inhibitor 
rate according to the number of patients registered was 0.011/100 patients/year. Due to the limited 
number of treatment years, comparisons between different concentrates are unreliable. In total, 12 
different plasma-derived FIX concentrates were used, with a total number of treatment years ranging 
from 4 to 334 per concentrate (Table 4). 
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Discussion: 
Main findings 
With data on 10771 treatment years in 9832 patients with non-severe haemophilia under 
surveillance, the present study reports on inhibitor development in one of the largest prospectively 
collected cohorts to date.  
For patients with non-severe haemophilia A the inhibitor rate was approximately 5 per 1000 
treatment years, and for haemophilia B 10 times less. Although more than half of the Inhibitors in 
haemophilia A developed in the first 50 EDs, inhibitor development continued with increasing 
exposure to FVIII. Inhibitor development rates were similar across currently available FVIII 
concentrates.  
  
Study design 
The design used in the present study has strengths and weaknesses. An important strength is the 
prospective data collection from a large number of centres throughout Europe, including centres of 
different size and countries using different treatment strategies. This variability increases the 
generalizability of the results and is in sharp contrast with national studies, which have more 
homogeneous treatment strategies, and international studies, which predominantly include large 
centres(7,20,29).  
Limitations include the lack of source data verification, the lack of detailed data on both inhibitors 
and non- inhibitors, and the unknown number of individual patients receiving treatment. As EUHASS 
was aimed to accrue large numbers of patients, we could not perform source data verification, 
collect data on additional risk factors for inhibitor development (such as treatment intensity, gene 
mutation or family history of inhibitors), or perform central confirmatory testing for inhibitors. 
Indeed, data control other than logical checks was not included in the original protocol. This was 
acknowledged and corrected during the project: all reports of adverse side effects are checked for 
logical mistakes, and all centres were asked to review their data and answer queries for the present 
analysis. Most centres checked their data and answered our queries, resulting in inclusion of 92% of 
centres and 83% of inhibitors reported. Only for Haemate P data still appeared inconsistent, and 
therefore it was decided not to calculate inhibitor rates for this concentrate. To address this issue, 
the electronic data collection system will be adapted.  
Lack of information on the number of individual patients receiving treatment during the four years of 
observation does not affect the calculation of inhibitor risk per treatment year, but it prevents us 
from making any estimation of the cumulative incidence of inhibitors in non-severe haemophilia, 
which is more relevant from the individual patients’ perspective. Likewise, lack of information on the 
number of EDs in the non-inhibitor patients makes it impossible to reliably estimate the cumulative 
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incidence of inhibitors during the first 50 EDs for non-severe patients. This makes it impossible to 
compare these data to the inhibitor rates in PUPs and PTPs with severe haemophilia. Only the data 
regarding the number of EDs at inhibitor development are unaffected by the lack of information on 
FVIII exposure in non-inhibitor patients and therefore can be compared to results from other 
studies..  
 
Comparison with other studies 
Inhibitor rate in non-severe patients was about three times higher than in PTPs with severe 
haemophilia A collected in EUHASS: 0.43/100 treatment years (CI 0.30-0.59) in non-severe versus 
0.15/100 treatment years (CI 0.10-0.22) in severe haemophilia A. For non-severe haemophilia B, the 
inhibitor rate was similar at 0.05/100 treatment years (CI 0.001-0.26) compared with 0.04/100 
treatment years  (CI 0.001-0.20) in PTPs with severe haemophilia B, but is based on the observation 
of only one inhibitor in each patient group (23). Comparisons with other studies reporting on non-
severe haemophilia are hampered by differences in study design. Large cohort studies present the 
lifetime inhibitor risk as cumulative incidence ranging from 6-13% in non-severe haemophilia A (11-
12,14) . For haemophilia B, the UK national registry reported no inhibitors in non-severe haemophilia 
B (http://www.ukhcdo.org/docs/AnnualReports/2012/), and the American Universal Data Collection 
database reported a prevalence of 0.33% (30). The largest and most important study on inhibitor 
development in moderate and mild haemophilia to date, the INSIGHT study, reported on 2711 
patients ever exposed to FVIII from 34 centres (12). Treatment was collected as EDs, and lifetime 
inhibitor risk was calculated according to EDs. In a subset of 1112 patients, 59 inhibitors occurred in 
25700 observation years, which would result in an inhibitor rate of 0.23/100 treatment years, if all 
patients were treated each year, or 0.46/100 treatment years if patients were treated every other 
year. The latter treatment intensity is more likely to reflect clinical practice, and this inhibitor rate is 
close to the inhibitor rate observed in the present study. Details on INSIGHT patients who developed 
inhibitors during 2000-2010 were similar to those observed in EUHASS: inhibitors occurred at a 
median age of 46 years (P25-P75: 18-65), after 32 EDs (P25-P75: 21-75), including 61% high titre 
inhibitors. The INSIGHT study included survival analysis according to EDs suggesting that inhibitor risk 
in non-severe haemophilia continued to increase after 50 EDs. There is an overlap between the 
INSIGHT and EUHASS studies as 20 centres participated in both during 2.25 years (Oct 2008-Dec 
2010). However, the only overlap reported consists of the characteristics of inhibitor patients. The 
INSIGHT study did not address inhibitor development according to concentrate nor the incidence 
rate of inhibitors according to 100 treatment years. Rather, it has focused on etiological factors 
including genetic risk factors(12) and the effects of surgery(31), while others have studied the effects 
of age on inhibitor risk(11). Unfortunately, these risk factors cannot be studied in the EUHASS 
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registry, which is focused on detecting the risk of inhibitor development according to different 
concentrates. Similar to findings in severe haemophilia patients, no difference according to 
concentrate type nor between plasma derived and recombinant FVIII concentrates was observed.  
 
Clinical relevance 
The importance of actively monitoring for inhibitor development in moderate and mild haemophilia 
is supported by the data presented here: inhibitors in non-severe haemophilia A occur more 
frequently than in PTPs with severe haemophilia, and continue to develop after 50 EDs. 
Unfortunately, EUHASS data do not permit assessment of inhibitor development according to age, 
EDs, or other risk factors. Other studies have shown that older patients, patients undergoing surgery 
and those with certain mutations have an increased inhibitor risk(11-12,31) . It has been described 
that at least half of the patients have high titre inhibitors, and clinical problems are caused by the 
reduced endogenous FVIII activity and increased rates of bleeding events (12,14). Although the 
power of the present study is limited by low numbers, these results do not give reason to select or 
avoid any of the products assessed.  
The observation that the number of non-severe patients treated is much lower than the number of 
patients monitored by centres, emphasizes the value of calculating inhibitor risk according to 
concentrate treatment years. Many mild haemophilia A patients are treated with Desmopressin 
which does not have an inhibitor risk as the released FVIII is endogenously produced. 
 
Conclusion: 
EUHASS is an international multicentre pharmaco-surveillance system covering a continuously 
growing open population. Further insights into the development of inhibitors in mild and moderate 
patients will be available in the future. 
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Table 1. Data analysed and inhibitors observed in non-severe haemophilia patients according to 
treatment status and diagnosis 
Centres included 68/74 (92%) 
Inhibitors included 40/48 (83%) 
Number of patients registered 9832/10940 (90%) 
 Haemophilia A Haemophilia B 
Number of patients registered 7969 1863 
Treatment years 8622 2149 
Inhibitors observed 39 1 
 
 
Table 2. Characteristics of inhibitor patients in non-severe haemophilia according to diagnosis  
 Haemophilia A 
median (P25-P75) 
Haemophilia B 
median (P25-P75) 
Number 39* 1 
Age (yrs) 35.3 (9.3-67.9) 26 
Moderate haemophilia 36% 0% 
Number of EDs before 
inhibitor development 
38 (20-80) 6 
Median 1st titre 4.0 (1.1-12.2) 5 
Inhibitors within the first 
50 EDs 
72% 100% 
% high titre within first 
two measurements 
51.3% 100% 
*Including 2 inhibitors on Haemate P that were not included in the overall calculation of inhibitor 
rate due to incomplete data on the number of patients at risk 
EDs = exposure days  
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Table 3. Inhibitor development according to concentrate types and individual recombinant 
concentrates  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*data for inhibitor development on Haemate P are not included 
due to incomplete data on the number of patients at risk,  
PTPs = previously treated patients 
rec = recombinant 
pd = plasma derived 
BHK = Baby hamster kidney cells 
CHO = Chinese hamster ovarian cells 
BDD = B-domain deleted 
 
 
  
 Inhibitors 
(N) 
Treatment years 
(N) 
Inhibitors (N/100 yrs)  
(95% CI) 
Haemophilia A    
Haemophilia A overall 37 8622 0.43  (0.30-0.59) 
FVIII rec 34 6546 0.52  (0.36-0.73) 
FVIII pd 3* 2076 0.14  (0.03-0.42) 
    
FVIII BHK 12 2993 0.40  (0.21-0.70) 
FVIII CHO full 11 2455 0.45  (0.18-0.73) 
FVIII CHO BDD 11 1088 1.01  (0.51-1.80) 
    
Advate 9 2335 0.39  (0.18-0.73) 
Helixate NexGen 5 1091 0.46  (0.15-1.07) 
Kogenate Bayer 7 1902 0.37  (0.15-0.76) 
Recombinate 2 121 1.66  (0.20-5.87) 
Refacto 3 130 2.30  (0.48-6.58) 
Refacto AF 8 958 0.84  (0.36-1.64)) 
    
Haemophilia B    
Haemophilia B overall 1 2149 0.05 (0.001-0.26) 
FIX pd 0 735 0.00  (0.00-0.50) 
FIX rec 
(Benefix) 
1 1414 0.07  (0.00-0.39) 
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